Zonisamide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Zonisamide |
| DrugBank ID | DB00909 |
| Brand Names (EU) | Zonegran |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.85% |
Approved Indication (EMA)
Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Tourette syndrome | 99.85% | DL |
| 2 | trichotillomania | 99.78% | DL |
| 3 | methemoglobinemia, alpha type | 99.64% | DL |
| 4 | methemoglobinemia | 99.63% | DL |
| 5 | Prinzmetal angina | 99.55% | DL |
| 6 | methemoglobin reductase deficiency | 99.53% | DL |
| 7 | manic bipolar affective disorder | 99.35% | DL |
| 8 | absence epilepsy | 99.24% | DL |
| 9 | fibromyalgia | 99.20% | DL |
| 10 | conjunctivitis | 99.16% | DL |
| 11 | trigeminal nerve neoplasm | 99.15% | DL |
| 12 | multifocal atrial tachycardia (disease) | 99.14% | DL |
| 13 | tendinitis | 99.12% | DL |
| 14 | myositis fibrosa | 99.12% | DL |
| 15 | idiopathic granulomatous myositis | 99.12% | DL |
| 16 | nephrogenic syndrome of inappropriate antidiuresis | 99.05% | DL |
| 17 | migraine disorder | 99.05% | DL |
| 18 | visual epilepsy | 99.04% | DL |
| 19 | idiopathic neonatal atrial flutter | 98.90% | DL |
| 20 | inclusion body myositis | 98.87% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.